Attempts to improve survival following curative surgery for non-small-cell lung cancer are reviewed. Most of these approaches have been designed to This paper reviews the results of nonspecific immunotherapy for lung cancer and then presents data from the cooperative study between Washington and Ottawa, using a specific approach to boost the immune resistance of patients with stage I lung cancer.
A pilot trial using specific active immunotherapy is described. Prolongation of survival four years after closure of the trial in those patients immunized, compared with non-immunized patients, has prompted two further clinical trials. A This paper reviews the results of nonspecific immunotherapy for lung cancer and then presents data from the cooperative study between Washington and Ottawa, using a specific approach to boost the immune resistance of patients with stage I lung cancer.
The pioneer in the use of living and later dead bacteria, whole or as extracts for the treatment of cancer, was the surgeon William Coley [1, 2] . Such material was given into the tumor, subcutaneously or intravenously. This therapy, initiated before the advent of radiotherapy or chemotherapy, was occasionally followed by regression of even metastasizing tumors. Because of associated fever, nausea, diarrhea, and even collapse of the patient, Coley called his treatment "toxins," not immunotherapy. Loeb [3] conducted a survey of the efficacy of Coley's toxins, writing to surgeons other than Coley. He concluded that, in not quite 5 percent of cases treated, a positive result was obtained. In 1915 Harmer [4] made a critical analysis of 134 cases, confirmed microscopically to be malignant. He concluded that the round cell type of sarcoma had the greatest chance of benefit and that the small round cell sarcoma had a much greater chance of regression. In 1969 the conditions considered necessary to allow success with Coley's toxins were listed [5] . Essential would be histologic evidence of a dense infiltrate of the tumor by lymphocytes and plasma cells, representing an intense but arrested immune response by the host. We now know that in lung cancer such a response is the exception, seen in only 16 percent of cases [6] . Thus in 84 percent of cases the use of bacterial extracts would cause morbidity but little benefit to the patient. This reasoning led to a search for more specific means of boosting host immunity to lung cancer, and to cooperation between Ottawa and Washington.
THE USE OF BACTERIA OR BACTERIAL PRODUCTS AS ADJUNCTIVE THERAPY OF CARCINOMA OF THE LUNG Bacille Calmette-Guerin (B.C. G.) Given by the Intradermal Route A five-year controlled study of B.C.G. and radiotherapy in inoperable lung cancer was reported by Pines [7] . Forty-eight patients received radiotherapy for advanced lung cancer. Thereafter 25 received B.C.G. regularly by Heaf gun; 23 patients received no B.C.G. Three years later all patients who received B.C.G. were dead; 22 of 23 controls were dead.
Another five-year study was reported by Edwards et al. [8] . Sixty patients received B.C.G. by subdermal injection, following surgery by one surgeon. Sixty consecutive surviving patients served as controls. No statistical evidence was found that B.C.G. influenced the survival rate nor was there any effect on involved lymph nodes or small metastases.
A study of 92 patients, strictly randomized following surgical resection of the tumor, was reported by Roscoe et al. [9] . Twenty-nine patients received B.C.G. by Heaf gun, 26 patients by intradermal injection, and 37 control patients received nothing. No Lowe et al. [12] fail to confirm this favorable effect of intra-pleural B.C.G. in a report of a controlled randomized clinical trial of 92 patients. No evidence of benefit was seen with a period of follow-up of 14 to 36 months. This is in contrast to the striking difference between controls and the B.C.G. patients over a similar time period reported earlier by McKneally and his colleagues [13] . No significant benefit of intra-pleural B.C.G. has been reported [14] in a large multicenter trial sponsored by the National Lung Cancer Study Group. A total of 383 stage I patients were randomized to receive intra-pleural B.C.G. or saline. The 56 recurrences were nearly equally distributed between the two groups.
No significant benefit (p = .11) was reported by Wright et al. [15] in a study of 134 patients who received B.C.G. intra-pleurally compared to a group who received placebo.
Intra-Pleural Corynebacterium Parvum
Stjernsward [16] has reported on a randomized clinical trial comparing intrapleural corynebacterium parvum (CP) versus placebo. Four hundred patients were evaluable. CP was found to be detrimental to the disease-free interval for well and moderately differentiated histologic diagnoses (p = 0.034). An increase in fever following CP was associated with a decrease in the disease-free interval.
It is of interest that the reports of naturally occurring empyema following surgical resection of lung cancer differ in their conclusions. The entire literature was reviewed by Brohee et al. [17] ; six reports of individual cases and five reports of original controlled studies. They concluded that the literature was contradictory due to uncontrolled variables. In their own study 148 male patients on register were examined. In curative surgical resection empyema had no benefit on survival (14 cases). In reductive surgery (20 cases with empyema) survival time was shortened (p = 0.025). A careful study was reported by Minasian et al. [18] of 50 patients who developed empyema after resection for lung cancer. Such patients were individually paired with patients who had not suffered this complication. Pairs were matched for age, sex, extent of operation, histology of the tumor, extent of primary spread, extent of lymphatic spread, and the use of postoperative radiotherapy. The results suggested that any immunological suppression of carcinoma cells due to sepsis in the pleural space was ineffective in prolonging survival More optimistic has been the report of Yamamura et al. [19] on the use of B.C.G. cell wall skeleton. Some 455 patients with lung cancer treated by surgery, irradiation, and/or chemotherapy were given B.C.G. cell wall, oil attached, intratumorally, or intracutaneously. Historical controls were used and it was concluded that survival was significantly prolonged (p = 0.0001).
Levamisole as Adjunctive Therapy of Carcinoma of the Lung Amery [20] has recently updated survival following the randomized trial of levamisole given to 96 patients, with 115 patients receiving a placebo. Benefit was seen in patients receiving a higher dose of levamisole, and was evident two years after surgery. Four years following surgery no effect was discernible.
Anthony et al. [21] , using the optimal dosage of levamisole, studied 318 patients in a randomized blind trial. A significantly poorer survival for resected lung cancer patients was seen in the patients who received levamisole, with a 15 percent excess of deaths in those 99 patients.
Wright et al. [15] also report on shortened survival of patients who received intrapleural B.C.G. plus levamisole, compared to controls. They conclude that the combination of levamisole and intra-pleural B.C.G. will be of no benefit.
THYMOSIN FRACTION V
In a study [22] [24] . The correlation between the appearance of a delayed hypersensitivity reaction (DHR) to the target antigen in skin testing and the onset of clinical disease was convincing [24] . The intensity of the DHR predicted the severity of the immunologically induced damage [25] . Such damage could be transferred by sensitized cells but not by serum; see the review by Waksman [24] . The [31, 32, 33, 34] , and squamous cell carcinoma [31, 33, 35, 36, 37, 38] . Onco fetal antigens have also been described [31, 33, 34, 36, 37, 39] . Cross reactivity of common tumor associated antigens is seen in human lung cancers [27, 29] and also in animal models of carcinogen-induced lung cancer [40, 41, 42, 43] . Low pH elution techniques have been used to isolate immunoglobulins from lung cancer tissue and pleural effusions [44] . Such antibodies reacted in significant titers with cells of squamous cell carcinoma and adenocarcinomas but not with cells of normal adult or fetal lung or of non-pulmonary tumors [45] . Various techniques in vitro have shown lymphocyte response of cancer patients to lung tumor-associated antigens: lymphoblastogenesis [46, 47, 48] , leucocyte migration inhibition [49, 50, 51, 52] , leucocyte adherence inhibition [53, 54] , and lymphocytotoxicity to autologous tumor cell suspensions [55] .
We chose to use high dose methotrexate (with citrovorum rescue) before immunization in some patients because this drug induces rebound overshoot of in vitro lymphocyte performance [28] . For this reason we used as controls patients who were not immunized but who received the drug in an identical fashion. In such patients such a short course of the drug alone was anticipated to have no effect on patient mortality.
METHODS AND MATERIALS The study was opened in March 1973 and closed in September 1976.
PATIENT SELECTION Patients were drawn from those having surgical removal of their tumor at the Ottawa Civic Hospital, the National Defence Medical Centre, Ottawa, and the Ottawa General Hospital. Careful staging for TNM [56] was assured by preoperative radiography, scans, mediastinoscopy, and postoperative consideration of the notes of the surgeon and pathologist. Fifty-two patients with Stage I disease are evaluated. Of these, 16 patients acted as a concomitant control group; they were operated upon by the same surgeons. The remaining 36 patients were randomized into one of three treatment groups.
Group I-Eight patients who received methotrexate (MTX) followed by citrovorum rescue once a month, for three months.
Group II -Immunotherapy. Fifteen patients who received allogeneic Tumor Associated Antigen (matched for histology) homogenized with Freund's complete adjuvant (FCA) once a month for three months.
Group III -Immunochemotherapy. Thirteen patients who were immunized seven to nine days after administration of MTX with citrovorum rescue once a month for three months.
In Table I are summarized all the relevant characteristics of the patients with Stage I disease.
Dose of Antigen
The preparation and characterization of antigens used for skin testing and immunization have been reported in detail [27] .
TUMOR-ASSOCIATED ANTIGENS (TAA) The mean total quantity of TAA given to patients in the immunotherapy group was 1,495 ,tg, (range 1,125 /g to 2,200 Ag). The mean total quantity of TAA given to the immunochemotherapy groups was 1,610 jig (range 900 to 3,000 p/g). An average of 500 Ag of antigen in 0.5 ml was homogenized with an equal volume of FCA (Difco Laboratories, Detroit, MI) which contains 10 mg of killed mycobacterium hominis per 10 ml, made up to 8.5 Bayol-F (mineral oil), and 1.5 ml Arlacel A (mannide mono-oleate). The homogenate was given intra-dermally into the deltoid region of the arm, the thigh, and again the arm at monthly intervals. Ulcers developed slowly at the site of injection with erythema and thinning of the skin, ulceration at seven to ten days, and showed gradual healing over months. They looked unsightly yet caused very little discomfort unless they became infected. Such superficial infection responded quickly to oral erythromycin. Occlusive dressings with sterile vaseline [57] . Those patients who died a non-cancer death have been handled as being lost to follow-up. Figure 1 shows the survival curves for the control and treated groups, with the one-sided 95 percent confidence limits for the control and treated groups.
The survival experience of the treated group may be seen to diverge significantly from the control group beyond 24 months. While 96 percent of the immunized group reached the second anniversary, only 72 percent of the controls did so. The corresponding values for the fourth anniversary are 82 percent and 50 percent, respectively. The overall comparison for the treated and control groups using Gehan's generalized Wilcoxon test [58] yielded a statistical significance ofp < .001.
Late Skin Testing with TAA: Following curative resection of lung, cancer patients were skin tested with soluble tumor-associated antigen, derived in most instances from allogeneic tumors, matched as closely as possible with the histology of the resected tumor. The usual skin test dose was 100 Ag in 0.1 ml. Not all patients could be tested in the later months after surgery; some died, some refused, and for others, distance from Ottawa made such testing impractical.
Non-Immunized Group. Stage I: Twelve patients were tested. Seven patients gave a weak to moderate reaction to tumor antigen; one of these patients died of lung cancer seven months later. Five patients gave no reaction on testing with tumor antigen, yet were able to give a positive reaction to at least one recall bacterial antigen; thus they were not completely anergic. Four of these patients died of lung cancer, 2, 7, 18, and 23 months after testing. Details of these skin tests are given in Table 3 .
Immunized Group: Eleven patients were tested at varying intervals following DISCUSSION A clear correlation between resistance to tumor growth and a delayed hypersensitivity reaction to soluble tumor-associated antigens has been shown by several workers in experimental animal tumor systems [59, 60, 61, 62] . In general such delayed hypersensitivity reactions last for 28-30 days. We believe that in our patients persistence of such hypersensitivity reactions to tumor antigens for five years or more is a sign of prolonged resistance to tumor growth.
The survival of our non-immunized patients compares almost exactly with the survival of all patients entered into the large multicenter trial of oral B.C.G. in Canada from 1973 to 1976 [10] . The significant improvement in the immunized group's survival may reflect resistance to tumor growth. Four patients had local recurrence of cancer yet survived 31, 36, 42, and 48 months following this recurrence and in three no chemotherapy was given at any time. This long survival is in direct contrast to the study of Green and Kern [63] . Of 1,018 patients followed over a 13-year period, 46 had locally recurrent lung cancer. Median survival for those patients was 11 months following recurrence, and only 5 percent survived three years or more.
In this trial it was decided to give the tumor-associated antigens homogenized with Freund's complete adjuvant since this is the practice in inducing auto-immune target organ damage and delayed hypersensitivity reactions to the target organ antigen. It is recognized that resistance to adenovirus oncogenesis has been shown if the antigen and Freund's complete adjuvant are given separately in hamsters, up to five days after virus inoculation [64] . Strong delayed hypersensitivity reactions can be induced in guinea pigs by using antigen and adjuvant homogenized or separately with a very wide range of antigen, 2 yg to 10 mg [65] . The favourable survival of patients with stage I squamous cell lung cancer [66] receiving Freund's complete adjuvant and separate doses of antigen, as skin tests, from 200 to 400 ,g, in the first four months, may indicate that the amount of tumor-associated antigen required is less than had been anticipated in the phase II Ottawa trial. A current multicenter trial in Canada and the United States should shed further light on this, as those patients randomized to receive Freund's complete adjuvant alone will not receive tumor-associated antigens as skin tests during the first year. Whether such nonspecific therapy will be effective in prolonging survival in such patients remains to be seen.
Conclusion: Active immunotherapy using tumor-associated antigens appears effective in prolonging survival of patients with Stage I lung cancer, following curative surgery.
